Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04049747 | Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer(IP4-CHRONOS) | completed | N/A | 100 | Imperial College LondonOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT05137067 | A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. | completed | Phase 2 | 90 | Optimal Health ResearchOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06883474 | Osteosclerotic Changes on CT Predict Survival in Prostate Cancer | completed | — | 211 | Sun Yat-sen UniversityOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT02420977 | Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer | completed | Early Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT05910229 | Telephone Paramedical Support Prior to the Radiotherapy Simulation Scanner for Patients with Prostate Cancer(RTEPROST) | completed | N/A | 120 | Groupe Hospitalier de Bretagne SudOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06559007 | Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants | completed | Phase 1 | 24 | Atridia Pty Ltd.INDUSTRY | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04318028 | An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer | completed | N/A | 20 | University of Southern CaliforniaOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04832958 | Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients | completed | Phase 2 | 81 | IRCCS San RaffaeleOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05389202 | Study of Prostate Perfusion Before Embolization in Patients With Symptomatic Prostate Adenoma(EMBOPERF) | completed | N/A | 45 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05332340 | Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered | completed | Phase 1 | 12 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04978519 | Effectiveness of Cryotherapy Study for Prostate Cancer | completed | N/A | 16 | Chinese University of Hong KongOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05697198 | PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine(PREFER) | completed | — | 1,429 | Labcorp Corporation of America Holdings, IncINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04428203 | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 21 | Zin W MyintOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01792687 | Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | completed | Phase 1 | 6 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06460454 | PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing(PROFLu) | completed | — | 100 | Central Hospital, Nancy, FranceOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT01309672 | S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | completed | Phase 2 | 41 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03073395 | Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer | completed | Phase 1 | 30 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04186819 | Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. | completed | Phase 3 | 356 | Blue Earth DiagnosticsINDUSTRY | 4 | Feb 26, 2025 | clinicaltrials |
| NCT04896580 | IIT2020-20-SHIRAZIP-WALK: Nature Walks | completed | N/A | 20 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03805594 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 43 | University of California, San FranciscoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05902637 | The Efficacy of Mapping for Cognitive Prostate Biopsy(MAPROSTATE) | completed | N/A | 175 | Marmara UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03400150 | BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007 | completed | N/A | 222 | BioProtectINDUSTRY | 6 | Feb 18, 2025 | clinicaltrials |
| NCT05110495 | IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy(WINGMEN) | completed | Early Phase 1 | 27 | University of OxfordOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02254746 | A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer | completed | N/A | 27 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06359821 | Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer | completed | Early Phase 1 | 4 | Sichuan UniversityOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827340 | Multiparametric Whole-Body MRI: a Game Changer in Metastatic Prostate Cancer | completed | — | 104 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT00984321 | A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer | completed | N/A | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03665922 | Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer | completed | N/A | 39 | University of PittsburghOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06507462 | A Diagnostic Prediction Model for Prostate Cancer in Patients With PI-RADS Score 3 | completed | — | 460 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 11, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05680675 | Dual-Tracer Theranostic PET | completed | N/A | 50 | University of UtahOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT00887198 | Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,088 | Janssen Research & Development, LLCINDUSTRY | 11 | Feb 4, 2025 | clinicaltrials |
| NCT02405858 | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | completed | Phase 4 | 51 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02663193 | Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability(REAAcT) | completed | — | 108 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03207594 | Improving Evidence-Based Care for Cancer Patients | completed | — | 128 | Medical University of South CarolinaOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05099679 | Pilot Study for Black Men With Prostate Cancer: Optimization Of Mental and Heart Health, the BOOM-Heart Study | completed | N/A | 14 | Stanford UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT01254864 | Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies | completed | Phase 2 | 190 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03103321 | Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer | completed | Phase 3 | 158 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04869488 | A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 93 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04703920 | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | completed | Phase 1 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04627948 | STHLM3 AS NorDCaP - a Followup Study of Men on Active Surveillance of Prostate Cancer(NorDCaP AS) | completed | — | 199 | Karolinska InstitutetOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT04487847 | 18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer(PICture) | completed | Phase 1 / Phase 2 | 75 | Radboud University Medical CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06773858 | Genetic Studies of Prostate Cancer Aggressiveness and Prognosis | completed | — | 2,291 | Karolinska InstitutetOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT00207636 | Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening | completed | N/A | 812 | Centers for Disease Control and PreventionFED | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer(VISION) | completed | Phase 3 | 861 | EndocyteINDUSTRY | 10 | Jan 13, 2025 | clinicaltrials |
| NCT03619980 | A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death | completed | — | 6,908 | Astellas Pharma Europe Ltd.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT01639859 | Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci(PROSTATE SSI) | completed | N/A | 30 | Hospices Civils de LyonOTHER | 1 | Jan 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2025source: clinicaltrials